Venture Capital News Daily
   Your Source for Venture Capital and Private Equity Financings
   Massinvestor/VC News Daily      
   Venture Capital News Daily on RSS Venture Capital News Daily on Facebook Venture Capital News Daily on Twitter
VC DATABASE   /   MOBILE APP  /  CELEBRITY VCs   /   VENTURE TRACKR   /   ARCHIVE   /   ABOUT US
VC-funded Company:


Vergent Bioscience
420 N. 5th Street, Ste 500
Minneapolis, MN 55401
https://www.vergentbio.com/

Vergent is a biotechnology company developing a tumor-targeted, fluorescent probe to help surgeons quickly identify and completely remove cancerous tissue during surgery. Surgery is often the first-line treatment for solid tumors and the prognosis of a procedure is highly correlated with achieving complete tumor removal. When injected prior to surgery, Vergent's molecularly-targeted probe binds to enzymes overexpressed in tumor tissue, activating a brightly fluorescing dye. The cancer "lights up," providing the surgeon a clear visual guide for the surgical removal of the tumor and associated metastases. Vergent's proprietary probe is under development for use in multiple cancers including lung, breast, ovarian, colorectal, and brain, among others.

Key Contact
NameTitleE-Mail
John SantiniPresident & CEO


Funding Events
DateAmountTypeInvestors
06/12/18$8,700,000Series A Spring Mountain Capital  
 
Massinvestor/VC News Daily
617-620-4606


© 2018 Massinvestor, Inc.